Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 19, 2011; 76 (16) Articles

Skin biopsy is useful for the antemortem diagnosis of neuronal intranuclear inclusion disease

J. Sone, F. Tanaka, H. Koike, A. Inukai, M. Katsuno, M. Yoshida, H. Watanabe, G. Sobue
First published March 16, 2011, DOI: https://doi.org/10.1212/WNL.0b013e3182166e13
J. Sone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Tanaka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Koike
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Inukai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Katsuno
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Yoshida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Watanabe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Sobue
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Skin biopsy is useful for the antemortem diagnosis of neuronal intranuclear inclusion disease
J. Sone, F. Tanaka, H. Koike, A. Inukai, M. Katsuno, M. Yoshida, H. Watanabe, G. Sobue
Neurology Apr 2011, 76 (16) 1372-1376; DOI: 10.1212/WNL.0b013e3182166e13

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
843

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Background: Neuronal intranuclear inclusion disease (NIID) is a progressive neurodegenerative disease characterized by eosinophilic hyaline intranuclear inclusions in neuronal and somatic cells. Because of the variety of clinical manifestations, antemortem diagnosis of NIID is difficult.

Methods: Seven skin biopsy samples from patients with familial NIID were evaluated histochemically, and the results were compared with those of skin samples from normal control subjects and from patients with other neurologic diseases. We also examined skin biopsy samples from patients with NIID by electron microscopy.

Results: In NIID skin biopsy samples, intranuclear inclusions were observed in adipocytes, fibroblasts, and sweat gland cells. These inclusions were stained with both anti-ubiquitin and anti-SUMO1 antibodies. Electron microscopy revealed that the features of the intranuclear inclusions in adipocytes, fibroblasts, and sweat gland cells were identical to those of neuronal cells. Approximately 10% of adipocytes showed intranuclear inclusions. No intranuclear inclusions were identified in the skin samples from normal control subjects and patients with other neurologic diseases.

Conclusions: Skin biopsy is an effective and less invasive antemortem diagnostic tool for NIID.

Neuronal intranuclear inclusion disease (NIID), also known as neuronal intranuclear hyaline inclusion disease, is a progressive neurodegenerative disease characterized by eosinophilic hyaline intranuclear inclusions in neuronal and visceral organ cells.1,–,4 Clinical manifestations of NIID are highly variable and can include pyramidal and extrapyramidal symptoms, cerebellar ataxia, dementia, convulsion, neuropathy, and autonomic dysfunction.1,–,6 Both sporadic and familial cases have been reported, and the onset of disease varies from infantile stages to late middle age.1,–,6 The antemortem diagnosis of NIID is difficult, and most of the reported cases of NIID are diagnosed by postmortem histopathologic examination. Some reports have described antemortem diagnosis of NIID by rectal biopsy5,6 and sural nerve biopsy.2 However, rectal biopsy has a risk of perforation,7 and sural nerve biopsy is applicable only in patients with sensory disturbance.2 To avoid the difficulty of antemortem diagnosis of NIID by rectal or sural nerve biopsy, we investigated skin biopsy samples from patients with familial NIID and compared the findings with those of samples from normal control subjects and from patients with other neurodegenerative diseases. Our results suggest that skin biopsy is a useful and safe tool for the antemortem diagnosis of NIID.

METHODS

Subjects.

Skin tissue samples were collected from autopsy samples, and skin biopsy samples were collected from patients at Nagoya University Hospital and from normal volunteers. Overall, skin biopsy samples from 7 patients with familial NIID from 2 pedigrees, as we reported previously,2 were analyzed. Patients with sporadic NIID were not included. For other neurodegenerative diseases, 3 biopsy samples from patients with Charcot-Marie-Tooth (CMT) disease with PMP22 duplication, 2 autopsy samples and one biopsy sample from patients with familial amyloid polyneuropathy (FAP), one biopsy sample from a patient with genetically diagnosed Huntington disease (HD), 3 biopsy samples from patients with spinocerebellar ataxia 3 (SCA3), 3 biopsy samples from patients with dentatorubral pallidoluysian atrophy (DRPLA), 2 autopsy samples and one biopsy sample from patients with spinal and bulbar muscular atrophy (SBMA), 3 autopsy samples from patients with sporadic amyotrophic lateral sclerosis (ALS), 2 autopsy samples and one biopsy sample from patients with Parkinson disease (PD), one autopsy sample and 2 biopsy samples from patients with multiple system atrophy (MSA), 2 autopsy samples and one biopsy sample from patients with progressive supranuclear palsy (PSP), and 8 samples from normal volunteers were analyzed. All the patients with CMT, FAP, SCA3, DRPLA, and SBMA were assessed genetically.

Standard protocol approvals, registrations, and patient consent.

The study was performed with approved protocols and informed consent in accordance with the institutional review board of Nagoya University School of Medicine. Written informed consent was obtained from all patients and normal volunteers.

Skin biopsy, immunohistochemistry, and electron microscopic study.

After local anesthesia, a 3-mm-diameter punch biopsy specimen was obtained at 10 cm above the lateral malleolus. All samples were fixed in 10% formalin. Sections of all samples (4 μm) were stained by hematoxylin & eosin (H&E), and immunohistochemical analysis was performed using a Ventana DISCOVERY system (Ventana Medical Systems, Tucson, AZ). Sections were incubated with anti-ubiquitin antibody (Z0458; DAKO, Glostrup, Denmark) and anti-SUMO1 antibody (sc-5308; Santa Cruz Biotechnology, Santa Cruz, CA) using the Ventana DAB Map kit. For immunofluorescence staining, sections were blocked with 4% goat serum and incubated in anti-ubiquitin antibody (P4D1; Santa Cruz Biotechnology). Bound anti-ubiquitin antibody was visualized using antimouse goat immunoglobulin G coupled with Alexa Fluor 488 (Molecular Probes, Eugene, OR). Nuclei were stained with 1.5 μg/mL 4′,6-diamidino-2-phenyindole di-lactate (DAPI). Samples for electron microscopy were fixed in glutaraldehyde in cacodylate buffer and embedded in epoxy resin.8

RESULTS

We performed more than 30 skin biopsies with no adverse reaction or accident. H&E-stained sections from patients with NIID demonstrated eosinophilic intranuclear inclusions in adipocytes, fibroblasts, and sweat gland cells in the dermis (figure 1, A–C). The nuclei of these cells were strongly stained basophilic, which made it difficult to observe inclusions in such small, dark-stained nuclei (figure 1, A–C). In anti-ubiquitin-stained sections using the DAB technique (figure 1, D–F), intranuclear inclusions were identified easily in all 7 NIID samples. However, erythrocytes and some secreted materials from the sweat glands were strongly stained with the anti-ubiquitin antibody, which made it difficult to distinguish these materials from intranuclear inclusions.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1 Histopathologic features of neuronal intranuclear inclusion disease (NIID) cells

(A–C) Hematoxylin & eosin (H&E) stain of adipocytes (A), fibroblasts (B), and sweat gland cells (C). (D–F) Immunostained samples of adipocytes (D), fibroblasts (E), and sweat gland cells (F) with anti-ubiquitin antibody using the DAB technique. (G–L) Electron microscopic images of adipocytes (G, J), fibroblasts (H, K), and sweat gland cells (I, L). (G–I) Lower magnification view of intranuclear inclusion (arrow). (J–L) Higher magnification view of each intranuclear inclusion. (M–O) Immunostaining with anti-SUMO1 antibody using the DAB technique of adipocytes (M), fibroblasts (N), and sweat gland cells (O). (P–T) Histopathologic features of intranuclear inclusion of neuronal cells of patients with NIID2: H&E stain of sympathetic ganglion neuron (P); immunostaining with anti-ubiquitin antibody of dorsal root ganglion neuron (Q); electron microscopic images of astrocyte of anterior horn in lower magnification (R) and higher magnification (S); and immunostaining with anti-SUMO1 antibody of sympathetic ganglion neuron (T). (A–F, M–Q, T) Scale bar = 10 μm. (G–I, R) Scale bar = 2.0 μm. (J–L, S) Scale bar = 500 nm.

By examination using electron microscopy, intranuclear inclusions in adipocytes, fibroblasts, and sweat gland cells showed common features (figure 1, G–L). These inclusions were composed of filamentous material and showed no limiting membrane. The nuclei of adipocytes were observed as entirely electron dense, but we were able to identify inclusions in the nuclei of adipocytes (figure 1, G and J). The nuclei of fibroblasts were less electron dense than those of adipocytes, and inclusions were recognized easily as electron-dense spherical bodies and filaments arranged in turbinate fashion (figure 1, H and K). In the sweat gland cells, intranuclear inclusions were observed as electron light material in the nucleus (figure 1, I and L).

We also examined anti-SUMO1 antibody immunoreactivity. SUMO1 is a small ubiquitin-like modifier protein that covalently conjugates to various intracellular target proteins to alter their cellular distribution, function, and metabolism. Neuronal intranuclear inclusions of patients with NIID are immunoreactive for SUMO1.9 Intranuclear inclusions in the dermal cells showed anti-SUMO1 immunoreactivity (figure 1, M–O), similar to results previously reported for NIID neuronal cells.1,9

These features of inclusions are identical to those of neuronal inclusions in patients with NIID (figure 1, P–T).2

Frequency of intranuclear inclusions.

We investigated the frequency of intranuclear inclusions in adipocytes, fibroblasts, and sweat gland cells using anti-ubiquitin antibody and DAPI for the purpose of distinguishing intranuclear inclusions from other ubiquitin-positive materials. Intranuclear inclusions were recognized readily as ubiquitin-positive inclusions within DAPI-positive nuclei under merge view (figure 2A). The frequency of intranuclear inclusion–positive adipocytes in NIID skin samples was approximately 10%, which represented the highest frequency among the 3 cell types (table).

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2 Immunofluorescence examination of skin samples from patients with neuronal intranuclear inclusion disease (NIID) and other neurodegenerative diseases

(A) Double immunofluorescence staining with anti-ubiquitin antibody and 4′,6-diamidino-2-phenyindole di-lactate (DAPI) in NIID skin samples from family I.2 Intranuclear inclusions were stained with anti-ubiquitin antibody (green) and these inclusions are included in the DAPI-positive nuclei in the merged view. Scale bar = 10 μm. (B–M) Double fluorescence staining for adipocytes in dermis with anti-ubiquitin antibody and DAPI in NIID family II2 (B), normal control (C), Charcot-Marie-Tooth disease (D), familial amyloid polyneuropathy (E), Huntington disease (F), spinocerebellar ataxia 3 (G), dentatorubral pallidoluysian atrophy (H), spinal and bulbar muscular atrophy (I), amyotrophic lateral sclerosis (J), Parkinson disease (K), multiple system atrophy (L), and progressive supranuclear palsy (M). Scale bars = 10 μm.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table

Frequency of intranuclear inclusions in adipocytes, fibroblasts, and sweat gland cells in patients with NIIDa

Immunofluorescence examination in NIID and a wide range of neurodegenerative diseases.

To examine the specificity of skin biopsy for the diagnosis of NIID, we investigated adipocytes in sections of skin samples from patients with NIID and other neurodegenerative diseases that were double-stained with anti-ubiquitin antibody and DAPI (figure 2, A and B). Intranuclear inclusions were not observed in normal control samples (figure 2C). No inclusions were observed in adipocytes from patients with CMT disease and FAP, who show clinical symptoms similar to those of patients with NIID2 (figure 2, D and E), or in patients with triplet-repeat diseases (HD, SCA3, DRPLA, and SBMA), ALS, PD, MSA, or PSP (figure 2, F–M). No intranuclear inclusions were observed in fibroblasts and sweat gland cells from normal control subjects and from patients with other neurologic diseases (data not shown).

DISCUSSION

In H&E-stained sections from patients with familial NIID, we observed intranuclear inclusions in adipocytes, fibroblasts, and sweat gland cells, but difficulty in observing the inclusions was encountered because of the size and density of the nuclei. Immunohistochemical analysis using anti-ubiquitin antibody with a DAB-based technique revealed intranuclear inclusions more distinctly than H&E staining. These results suggest that double fluorescence staining with anti-ubiquitin antibody and DAPI is a more reliable method to detect intranuclear inclusions in skin samples from patients with NIID, and we recommend this method for the diagnosis of NIID.

Intranuclear inclusions detected in adipocytes, fibroblasts, and sweat gland cells in skin samples were visible in H&E-stained sections, were positive for anti-ubiquitin antibody and anti-SUMO1 antibody, and showed filamentous materials and no limiting membrane. These features of inclusions are identical to those reported for NIID inclusions in neuronal cells (figure 1).1,–,4,9 We suggest that the intranuclear inclusions in dermal cells have a pathologic background similar to that of neuronal cells and are useful for NIID diagnosis. Furthermore, because no intranuclear inclusions were observed in dermal cells from normal control samples and other neurodegenerative disease skin samples, skin biopsy is a powerful tool for the differential diagnosis of NIID from other neurologic diseases.

The examination of a few slides of double-immunostained skin samples may be sufficient for the diagnosis of NIID because the frequency of intranuclear inclusions in adipocytes was approximately 10%. Skin biopsy is an accepted and established technique.10 It requires only local anesthesia and is safer and easier and presents less stress to patients than rectal biopsy or sural nerve biopsy. Taken together, our results suggest that skin biopsy is an acceptable and less invasive tool for the antemortem diagnosis of NIID.

DISCLOSURE

Dr. Sone reports no disclosures. Dr. Tanaka has received research support from the Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (21659221, 22390175), and a grant from the Ministry of Health, Welfare and Labor of Japan. Dr. Koike has received research support from the Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (21591076), and a grant from the Ministry of Health, Welfare and Labor of Japan. Dr. Inukai reports no disclosures. Dr. Katsuno received research support from the Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (21689024, 2110005). Dr. Yoshida received research support from the Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (21500339), and a grant from the Ministry of Health, Welfare and Labor of Japan. Dr. Watanabe reports no disclosures. Dr. Sobue serves on scientific advisory boards for Kanae Science Foundation for the Promotion of Medical Science, Naito Science Foundation, and has received research support from the Ministry of Education, Culture, Sports, Science and Technology of Japan (21229011, 17025020, 09042025), the Ministry of Welfare, Health and Labor of Japan, and the Japan Science and Technology Agency, Core Research for Evolutional Science and Technology.

Footnotes

  • Study funding: Supported by a 21st Century Center of Excellence (COE) grant and a global COE grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan and by a grant from the Ministry of Health, Welfare and Labor of Japan.

  • Editorial, page 1368

  • ALS=
    amyotrophic lateral sclerosis;
    CMT=
    Charcot-Marie-Tooth;
    DAPI=
    4′,6-diamidino-2-phenyindole di-lactate;
    DRPLA=
    dentatorubral pallidoluysian atrophy;
    FAP=
    familial amyloid polyneuropathy;
    HD=
    Huntington disease;
    H&E=
    hematoxylin & eosin;
    MSA=
    multiple system atrophy;
    NIID=
    neuronal intranuclear inclusion disease;
    PD=
    Parkinson disease;
    PSP=
    progressive supranuclear palsy;
    SBMA=
    spinal and bulbar muscular atrophy;
    SCA3=
    spinocerebellar ataxia 3.

  • Received August 6, 2010.
  • Accepted November 17, 2010.
  • Copyright © 2011 by AAN Enterprises, Inc.

REFERENCES

  1. 1.↵
    1. Woulfe JM
    . Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a work in progress. Neuropathol Appl Neurobiol 2007;33:2–42.
    OpenUrlPubMed
  2. 2.↵
    1. Sone J,
    2. Hishikawa N,
    3. Koike H,
    4. et al
    . Neuronal intranuclear hyaline inclusion disease showing motor-sensory and autonomic neuropathy. Neurology 2005;65:1538–1543.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Takahashi-Fujigasaki J
    . Neuronal intranuclear hyaline inclusion disease. Neuropathology 2003;23:351–359.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Lindenberg R,
    2. Rubinstein LJ,
    3. Herman MM,
    4. Haydon GB
    . A light and electron microscopy study of an unusual widespread nuclear inclusion body disease: a possible residuum of an old herpesvirus infection. Acta Neuropathol 1968;10:54–73.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Kulikova-Schupak R,
    2. Knupp KG,
    3. Pascual JM,
    4. Chin SS,
    5. Kairam R,
    6. Patterson MC
    . Rectal biopsy in the diagnosis of neuronal intranuclear hyaline inclusion disease. J Child Neurol 2004;19:59–62.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Zannolli R,
    2. Gilman S,
    3. Rossi S,
    4. et al
    . Hereditary neuronal intranuclear inclusion disease with autonomic failure and cerebellar degeneration. Arch Neurol 2002;59:1319–1326.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Tanaka S,
    2. Oka S,
    3. Chayama K
    . Colorectal endoscopic submucosal dissection: present status and future perspective, including its differentiation from endoscopic mucosal resection. J Gastroenterol 2008;43:641–651.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Koike H,
    2. Iijima M,
    3. Mori K,
    4. et al
    . Nonmyelinating Schwann cell involvement with well-preserved unmyelinated axons in Charcot-Marie-Tooth disease type 1A. J Neuropathol Exp Neurol 2007;66:1027–1036.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Pountney DL,
    2. Huang Y,
    3. Burns RJ,
    4. et al
    . SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease. Exp Neurol 2003;184:436–446.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Lauria G,
    2. Cornblath DR,
    3. Johansson O,
    4. et al
    . EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol 2005;12:747–758.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis

Dr. Robert Pitceathly and Dr. William Macken

► Watch

Related Articles

  • Neuronal intranuclear inclusion diseaseNo longer a pain in the butt

Topics Discussed

  • All Clinical Neurology
  • Diagnostic test assessment

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Editorials
    Neuronal intranuclear inclusion disease
    No longer a pain in the butt
    Keith A. Josephs et al.
    Neurology, March 16, 2011
  • Clinical/Scientific Notes
    Neuronal intranuclear inclusion disease showing intranuclear inclusions in renal biopsy 12 years earlier
    Mikiko Motoki, Hideto Nakajima, Tomoe Sato et al.
    Neurology, October 03, 2018
  • Articles
    Neuronal intranuclear hyaline inclusion disease showing motor-sensory and autonomic neuropathy
    J. Sone, N. Hishikawa, H. Koike et al.
    Neurology, November 21, 2005
  • Article
    Identification of GGC repeat expansion in the NOTCH2NLC gene in amyotrophic lateral sclerosis
    Yanchun Yuan, Zhen Liu, Xuan Hou et al.
    Neurology, September 28, 2020
Neurology: 100 (11)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise